the thermostability of an integral membrane protein (Mp) in detergent solution is a key parameter that dictates the likelihood of obtaining well-diffracting crystals that are suitable for structure determination. However, many mammalian Mps are too unstable for crystallization. We developed a thermostabilization strategy based on systematic mutagenesis coupled to a radioligand-binding thermostability assay that can be applied to receptors, ion channels and transporters. It takes ~6-12 months to thermostabilize a G-protein-coupled receptor (Gpcr) containing 300 amino acid (aa) residues. the resulting thermostabilized Mps are more easily crystallized and result in high-quality structures. this methodology has facilitated structure-based drug design applied to Gpcrs because it is possible to determine multiple structures of the thermostabilized receptors bound to low-affinity ligands. protocols and advice are given on how to develop thermostability assays for Mps and how to combine mutations to make an optimally stable mutant suitable for structural studies. the steps in the procedure include the generation of ~300 site-directed mutants by ala/leu scanning mutagenesis, the expression of each mutant in mammalian cells by transient transfection and the identification of thermostable mutants using a thermostability assay that is based on binding of an 125 I-labeled radioligand to the unpurified, detergent-solubilized Mp. Individual thermostabilizing point mutations are then combined to make an optimally stable Mp that is suitable for structural biology and other biophysical studies. 24, 25 , and the rat neurotensin receptor (NTSR1) bound to a peptide agonist 26 . These structures have been instrumental in determining the differences in efficacy of ligands to β 1 AR and the conformational changes in A 2A R upon agonist binding. The structure of NTSR1 bound to the C-terminal portion of the native agonist neurotensin remains the only structure of a GPCR bound to a peptide agonist, although further structures of other thermostabilized NTSR1 mutants in different agonist-bound conformations have since been determined 27,28 . There is currently no known structure for a ligand-free GPCR 29 , highlighting the importance of ligands in structural biology projects. Conformational thermostabilization forms the foundation of the StaR methodology developed by Heptares Therapeutics 30 , which has been used to determine the structures of multiple receptors, including A 2A R bound to a range of antagonists 25, as well as compounds derived from their structure-based drug design program 24 , the corticotrophin-releasing factor receptor 31 and the metabotropic glutamate receptor 32 . Thermostabilizing mutations have also been essential for the structure determination, by other research groups, of the GPCRs CCR5 (ref. 33) and GPR40 (ref. 34), the Drosophila dopamine transporter 35 and an ion channel, the NMDA receptor 36 .
IntroDuctIon
Structure determination of integral MPs is not a trivial undertaking, and the numbers of their structures in the Protein Data Bank are still underrepresented compared with those of soluble proteins. However, there have been many technological developments in the methodology concerning aspects ranging from gene to structure that are contributing to the exponential increase in the number of MP structures determined 1 . Probably the most important aspect of any structural biology project on MPs that dictates success is the choice of the target, with the highest probability of success correlating with high thermal stability in detergent solution, high expression levels and few post-translational modifications. One highly pragmatic approach is to identify those MPs that are most amenable to structure determination-i.e., MPs that are readily overexpressed and are stable in short-chain detergents. This process is facilitated by using MPs that are fused at the C terminus to GFP; this allows a rapid assessment of both expression levels 2, 3 and stability 4 of the detergent-solubilized unpurified MP by fluorescence-detection size-exclusion chromatography 5 . Parallel screening of thousands of genes from different bacteria expressed in Escherichia coli has resulted in the determination of structures for numerous MPs and is highly amenable to highthroughput structural biology techniques 6 . Similar methodologies are proving to be successful for the expression of eukaryotic MPs in yeast 7, 8 , but the success rates for structure determination for eukaryotic MPs are markedly lower, which is probably because of the poor stability of these proteins in detergent solution as compared with that of their prokaryotic homologs 9 . This screening approach also does not address the problem faced when the structure of a specific, unstable MP is required, rather than the structure of a distantly related homolog.
One solution to improve the stability of any MP is to add a high-affinity inhibitor or ligand to membranes and then to solubilize and purify the MP-ligand complex. Improvements in stability can be marked, and such improvements usually occur in relation to increased affinity and decreased off-rate, although the relationship between all these factors is not always clear-cut. This approach has been particularly successful in the structure determination of GPCRs 10 , where there is often a large selection of inhibitors (antagonists) or high-affinity activators (agonists) that have resulted from decades of drug development by academic research groups and pharmaceutical companies. However, if the ligands that are available do not increase the stability sufficiently for structure determination, then the proteins themselves can be thermostabilized by a systematic program of mutagenesis and screening 11 , which has been termed conformational thermostabilization due to its ability to stabilize a single conformation of a receptor [12] [13] [14] . Thus, if selection of thermostable mutants is performed using an antagonist, then the ultimate thermostabilized receptor is preferentially in the inactive conformation. Conversely, selection with an agonist results in a receptor that is preferentially in an active-like state. We have determined structures of a number of thermostabilized GPCRs that were either previously challenging or intractable before thermostabilization; these include the turkey β 1 -adrenergic receptor (β 1 AR) bound to 12 different ligands (inverse agonist 15 , agonists 16 , partial agonists 16 , weak A mutagenesis and screening strategy to generate optimally thermostabilized membrane proteins for structural studies partial agonists (antagonists) [17] [18] [19] [20] and biased agonists 21 ), the human adenosine A 2A receptor (A 2A R) bound to three different agonists 22, 23 and four different antagonists 24, 25 , and the rat neurotensin receptor (NTSR1) bound to a peptide agonist 26 . These structures have been instrumental in determining the differences in efficacy of ligands to β 1 AR and the conformational changes in A 2A R upon agonist binding. The structure of NTSR1 bound to the C-terminal portion of the native agonist neurotensin remains the only structure of a GPCR bound to a peptide agonist, although further structures of other thermostabilized NTSR1 mutants in different agonist-bound conformations have since been determined 27, 28 . There is currently no known structure for a ligand-free GPCR 29 , highlighting the importance of ligands in structural biology projects. Conformational thermostabilization forms the foundation of the StaR methodology developed by Heptares Therapeutics 30 , which has been used to determine the structures of multiple receptors, including A 2A R bound to a range of antagonists 25 , as well as compounds derived from their structure-based drug design program 24 , the corticotrophin-releasing factor receptor 31 and the metabotropic glutamate receptor 32 . Thermostabilizing mutations have also been essential for the structure determination, by other research groups, of the GPCRs CCR5 (ref. 33 ) and GPR40 (ref. 34) , the Drosophila dopamine transporter 35 and an ion channel, the NMDA receptor 36 .
The thermostabilization methodology that we devised was developed initially between 2005 and 2008 during the thermostabilization of three different GPCRs: β 1 AR 13 , A 2A R 12 and NTSR1 14 . They were chosen because prior work by our colleagues G.F.X. Schertler and R. Grisshammer at the Laboratory of Molecular Biology, Cambridge, had already led to their functional expression and purification [37] [38] [39] . However, by 2005, no crystals had been obtained for any of the targets, which we ascribed to their poor stability in short-chain detergents. The thermostabilization methodology was then further refined on the original three receptors [40] [41] [42] [43] and expanded to include a neurotransmitter transporter: the cocaine-sensitive serotonin transporter (SERT) 44, 45 . The protocol described in this paper is therefore based on our experiences with all these receptors, but the example given is that used for the thermostabilization of SERT 44 , because this is what we use for any new project.
Thermostability assays for MPs
Before embarking on the lengthy and costly program to thermostabilize an MP, it is important to consider both the desirability and feasibility of the project (Box 1). The key steps in developing a thermostabilization procedure for an MP are as follows: (i) express the MP in a functional form; (ii) solubilize the MP in detergent; and (iii) perform a thermostability assay (Fig. 1) . Each of these steps needs to be optimized for the wild-type MP before site-directed mutagenesis is started, and the mutants need to be assessed for thermostability. The discussion in the rest of the paper will describe methodologies and experiences with GPCRs and transporters that are normally found in the plasma membrane of mammalian cells. Slightly different strategies may be required if the MP of interest is found in intracellular organelles such as the mitochondria or endoplasmic reticulum, but the three requirements above remain imperative and will be discussed in more detail below.
Functional expression of an MP. In theory, any expression system could be used to produce the MP, and we have used both inducible expression from the lac promoter in E. coli [12] [13] [14] and transient transfection of mammalian cells, using either constitutive expression 42 or tetracycline-inducible expression 44 . However, regardless of the technique used, the receptor must be expressed at reasonably high levels so that expression of the mutants can be performed in parallel on a small scale (5 ml of E. coli culture or a single well of a six-well plate (10 cm 2 ) of mammalian cells) and high throughput can be achieved. In addition, the expression
Box 1 | Initial considerations • tIMInG 2-3 months
Before starting to even consider whether a MP should be thermostabilized, there are a number of important factors to consider and information that is needed.
1. Is thermostabilization really required? The process is time-consuming and costly, and it demands skills and expertise that are not always found in a structural biology lab. If it is only a matter of determining a single structure, could other techniques be more practicable and be easier to implement? 2. Are suitable ligands available that bind to the MP with high affinity, preferably better than 100 nM? Are they available in a radiolabeled form? 3. Are there detailed protocols for radioligand binding assays in the literature? If there are, this will help in the initial choice of buffer conditions. 4. Is there any information in the literature with respect to expression of the target MP?
Once it is decided that thermostabilization should go ahead, it is essential to perform initial studies to demonstrate the feasibility of the process.
host must be easy to lyse with detergent, again on a small scale, and for multiple samples in parallel. E. coli is more problematic to lyse than mammalian cells, because its cell wall needs to be broken, efficiently and rapidly, by a combination of lysozyme treatment and freeze-thaw cycles. By contrast, the plasma membrane of mammalian cells is readily solubilized upon the addition of detergent. We prefer using mammalian cells to routinely express mammalian MPs for thermostabilization because such MPs are more efficiently expressed in a correctly folded functional state than if they are expressed by E. coli or yeast [46] [47] [48] .
In an ideal world, expression would be sufficiently high in transiently transfected mammalian cells that a single well of a 96-well plate would yield sufficient MPs for screening each mutant for thermostability. As 300-350 mutants are typically required to find 10-20 thermostabilizing mutations in a small GPCR, this would represent excellent throughput, although more frequently cells have to be grown in six-well plates because of low expression and/or low specific activity of a radiolabeled ligand. Optimization of transient transfection (Box 2, Steps 12-17) will ensure that the MP is expressed at the plasma membrane in optimal amounts. If too much plasmid is used in transient transfections, some MPs will aggregate and remain in an inactive form within the cell (Fig. 2) . Including a C-terminal or N-terminal GFP tag on the receptor is exceedingly useful in the initial stages of the project because fluorescence microscopy allows a rapid assessment of how efficient the transfection is (what percentage of cells express the protein) and also of whether a substantial proportion of the protein is intracellular (probably misfolded) or at the plasma membrane (probably folded and functional) 49 . For the SERT, if too much plasmid was added to cells, the expressed protein was predominantly intracellular (Fig. 2) and no functional transporter could be detected. This is consistent with difficulties that are encountered while expressing SERT 50 ; these arise because N-glycosylation is essential for efficient folding 51 and for the recruitment of molecular chaperones 52 . By contrast, other MPs such as corticotrophin-releasing factor receptor (Fig. 2) are expressed at the cell surface regardless of how much plasmid is added in a transient transfection.
Detergent-solubilization of the MP. The choice of detergent is critical for maintaining the MP in a biologically relevant state and therefore for the success of the radioligand binding assay performed on the detergent-solubilized MP 53 . Detergents have a spectrum of 'harshness', which refers to the ability of the detergent to inactivate MPs 54 . Mild detergents include digitonin, lauryl maltose neopentyl glycol (LMNG) and dodecylmaltoside (DDM) (in approximate decreasing order of mildness), whereas harsh detergents include lauryldimethylamine-N-oxide, (LDAO), nonylglucoside (NG), SDS and octylglucoside (OG) (in approximate increasing order of harshness). The ability of a detergent to inactivate an MP increases as the detergent head group decreases in size and also as the hydrophobic portion of the detergent decreases in size. This has also been observed when the thermostability of an ultrastable β 1 AR mutant was measured in different detergents 41 . However, there is also an important 'chemical' component, which is probably due to specific interactions between the MP and the detergent, consistent with the observation that ordered detergent and lipid molecules are often observed in high-resolution structures of MPs 55, 56 . Thus, thermostabilized β 1 AR is very stable in most detergents, but it is rapidly inactivated by polyoxyethylene detergents, such as C12E8, which was used to crystallize the sarcoplasmic reticulum Ca 2+ -ATPase 57 . Sometimes, the addition of lipids or sterols may improve the stability of the MP, such as is done in the stabilization of DDM-solubilized GPCRs through the addition of cholesteryl hemisuccinate (CHS) 37 . It is important to remember that the addition of a ligand/inhibitor to membranes before solubilization can substantially improve the amount of functional MP extracted such that ligand binding is measurable, whereas if the ligand is added after solubilization, no binding may be observed. This reflects the marked difference between the stability of a ligand-free MP as compared with that of a ligand-bound MP; in this context 'ligand' could be an inhibitor, substrate, antagonist, agonist or conformation-specific antibody. The choice of detergent to extract a MP in a functional state is entirely empirical and must be determined for each MP separately. However, digitonin (and the chemically similar detergent glycol-diosgenin, GDN 58 ) is probably one of the mildest detergents, and it should solubilize at least a proportion of most MPs in a functional form that is suitable for the development of the thermostability assay.
Development of a thermostability assay. The radioligand thermostability assay is at the heart of the conformational thermostabilization strategy and therefore warrants careful development to ensure the identification of thermostable mutants with a low level of false positives. There are three main advantages of using a radioligand for measuring thermostability. First, measurements can be performed on detergent-solubilized cells, so each mutant does not have to be purified. Second, the assays are very sensitive, so only a few picomoles of MP are required per assay point, thus requiring only small volumes of cell culture to produce a substantial signal. Third, radioligands are exquisite indicators of whether a protein is correctly folded, because side chains from multiple different transmembrane α-helices-and sometimes loop regions as well-all participate in ligand binding. This ensures that the thermostabilized MP has a biologically relevant conformation and its structure will therefore be informative. If a radioligand for the target MP is unavailable, other assays could be used, provided that they can detect whether the MP is correctly folded or not. For example, conformation-specific antibodies could be used to detect correctly folded proteins if they were fluorescently labeled. Before starting the development of a thermostability assay in detergent, it is essential to define conditions that allow radioligand binding to the MP in whole cells or membranes (Box 3), and this will also allow an estimation of the number of cells required for the assays in detergent described below.
To determine whether a detergent-solubilized MP binds a radioligand, a high-affinity ligand is incubated with cells and then the radioligand-bound MP is solubilized with detergent. The radioligand in solution is then separated from the receptor-bound radioligand, with the latter amount determined by scintillation counting (Fig. 3) . Note that because the assays are performed on unpurified receptors, it is important to use a cell type that does not endogenously express a protein that also binds the radioligand with high affinity. Although the assay itself is simple in concept, in reality the format of the assay is dictated by the physicochemical characteristics of the radioligand and the properties of the receptor. These two factors will be discussed separately below.
An ideal choice of radioligand is one that binds with high affinity to the receptor (apparent K D between 0.1 nM and 100 nM) and has a slow off-rate. Sensitivity is improved if the radioligand is labeled with 125 I, but 3 H-labeled ligands also work perfectly well. Separation of receptor-bound radioligand ('bound' radioligand) from the radioligand remaining in solution ('free' radioligand) can be achieved by using a small disposable gel filtration column
Box 2 | Development of a transient transfection protocol for MP expression (Steps 12-17): • tIMInG 2-3 weeks
There are many protocols for transient transfection of mammalian cells using either proprietary cationic amphiphiles such as GeneJuice and Lipofectamine or off-the-shelf reagents such as PEI. The effectiveness of the transient transfection is dependent on the healthiness of the cells (they should be doubling every ~24 h) and the transfection reagent used. We have noticed that some MPs are better expressed using one transfection reagent as compared with another, even when the vectors are identical. It is unclear as to why this is the case, so for a new target we test all three of the above transfection reagents. For MP functional expression, the most crucial factor is the amount of mRNA produced in the cell, because too much may lead to nonfunctional expression of the MP, as was observed for SERT 44 . We therefore use an inducible mammalian promoter, which allows us to control the level of expression by altering both the amount of plasmid in the transfection mix and the amount of inducing agent. If MPs are expressed with a C-terminal GFP tag, then cells may be observed by fluorescence microscopy 12-48 h after transfection to determine the optimal time for cell surface expression as opposed to the accumulation of intracellular aggregates, which are usually composed of misfolded MPs 49 . Some examples are shown in Figure 2 .
The amount of MP expressed per cell needs to be high enough for the high-throughput thermostability assays (Box 3). A typical iodinated radioligand such as 125 I-RTI55 has a specific activity of 81.4 TBq/mmol, which means that you will need 2.047 × 10 −15 moles of SERT bound to 125 I-RTI55 to give 10,000 d.p.m. in a scintillation counter. We frequently use 50,000 cells per assay point, which means that we would need only 25,000 copies of SERT per cell to give 10,000 d.p.m. (equivalent to 2 µg/l of cells, assuming 10 6 cells per ml). This is a very low level of expression considering that for structural studies we would be aiming for expression levels in the range of 1 mg/l. A confluent six-well tissue plate would be expected to yield ~300,000 HEK293 cells upon harvesting. However, if a tritiated ligand were to be used for the thermostability assays, expression levels would need to be higher and/or more cells would have to be used, because the specific activity of a typical tritiated ligand may be only 1.1 GBq/mmol-i.e., 74-fold lower than for the iodinated ligand. 
Box 3 | Development of a thermostability assay: • tIMInG 1-3 months
The thermostability assay of detergent-solubilized MP is the key aspect of the whole thermostabilization process. For reliable results in the high-throughput format, we aim to have a signal-to-noise ratio of ~10:1. There are two main variables in the assay: the physicochemical properties of the radioligand and the stability of the detergent-solubilized receptor. During the development of the thermostability assay, each of these needs to be considered carefully. For example, hydrophobic ligands may partition into detergent micelles, which may give rise to high backgrounds (high d.p.m. in the flowthrough in the absence of an MP), as lipid-detergent micelles may be reasonably large-e.g., a micelle of dodecylmaltoside has an apparent molecular weight of ~50-70 kDa. Assay development using mini gel filtration columns processed by centrifugation for speed ('spin columns') follows three main steps: (i) development of a radioligand-binding assay for the MP in whole cells or in purified membranes; (ii) definition of conditions in which the radioligand in detergent-containing buffers remains within a spin column and does not appear in the eluate; (iii) definition of conditions in which the detergent-solubilized radioligand-bound MP appears in the eluate.
i. Development of a radioligand-binding assay in membranes.
Very often, inspection of the literature will identify appropriate conditions for the binding of a radioligand to a specific MP. Ideally, the ligand should bind with high affinity-i.e., better than 100 nM. If the off-rate of the ligand is too fast, then dissociation may occur while the radioligand-MP complex is loaded onto and passing through the mini SEC column. Factors that affect ligand binding such as salt concentration and pH must be optimized and will be dependent on the target MP. Inclusion of blocking agents such as 0.1% (wt/vol) BSA and 0.1% (wt/vol) bacitracin may decrease the amount of nonspecifically bound radioligand (e.g., binding to the membrane surface), thus improving the signal-to-noise ratio.
ii. Development of a spin assay that retains the radioligand in the column. The 'gold-standard' spin assay that we use initially to develop a thermostability assay uses Sephadex G25 (medium) in a mini spin column (Fisherbrand screening columns), and it is ideal for small water-soluble radioligands such as 125 I-RTI55. The buffer used for both the assay and the gel filtration medium is identical to the buffer that gives good binding of the radioligand to the membranebound MP. Initially, a range of mild detergents should be tested, such as 0.1% (wt/vol) digitonin (or GDN), 0.1% (wt/vol) LMNG and 0.1% (wt/vol) DDM. Note that the concentrations of all the detergents are well above their respective critical micellar concentrations (CMCs) and have been found to be sufficient to solubilize MPs from the small amounts of mammalian cells used in these assays 42 . There is ~0.2 mg of total protein in 1 million HEK293 cells, as assessed by an amido black protein determination assay 82 , which will allow readers to correlate our solubilization conditions with those used in their labs. Higher amounts of detergents (up to 1% (wt/vol)) may improve solubilization efficiencies, particularly if the MP of interest is expressed at low levels in bacteria or yeast. Procedure 1. Add 100 g of dry Sephadex G25 (medium) to 1 liter of buffer containing 0.1% (wt/vol) detergent in a glass bottle and leave the mixture to equilibrate overnight at 4 °C. 2. Remove excess buffer from the swollen Sephadex to leave a ratio of 2:1 resin:buffer (vol:vol). 3. Prepare 180 µl of assay mixture. For these initial tests, this will be buffer + 0.1% (wt/vol) detergent + radioligand at a final concentration of 5-10× the K D for binding to the MP of interest. Eventually, this will also contain detergent-solubilized MP. 4. Thoroughly resuspend the resin by inverting the bottle. 5. Add 3.6 ml of resuspended resin to each spin column, pre-placed in a 10-ml test tube. Prepare three columns for each assay mixture to be tested, as each assay point should be determined in triplicate. Use a 5-ml automatic pipettor to pipette the resin into the columns and mix the resin thoroughly by inversion after every three columns poured, as it starts to settle out. It is crucial to have the same volume of resin in each tube for reproducible results. The columns can be poured a few hours before use and left at 4 °C. 6. Prespin the columns in a swing-out rotor in a benchtop centrifuge in a cold room (4 °C) at 275g for 3 min. Remove the spin columns from the test tubes and place onto scintillation vials. After the prespin, the columns should be used in a few minutes. 7. Load columns with 50 µl of assay mixture slowly, with the pipette tip near the center of the resin surface. A maximum of ~16 columns should be loaded at one time, and each assay point should be determined in triplicate. 8. Spin the columns for 4 min at 4 °C and 375g. 9. Discard the columns, add the scintillant to the scintillation vials, cap them and then count in a scintillation counter. Also add 5 µl of assay mixture in triplicate to determine the total radioligand concentration in the assay mixture.
The expected results are that the radioligand is retained on the column. If in 50 µl of assay mixture there was a total of 200,000 d.p.m. 125 I-RTI55, then in the flow-through from the column there should be only 100-200 d.p.m.
iii. Development of a spin assay that measures binding to a detergent-solubilized MP.
The assay in section ii above is repeated, but now the assay mixture loaded onto the column is made up of detergent-solubilized membranes containing the MP of interest. Initially, a range of mild detergents should be tested such as 0.1% (wt/vol) digitonin (or GDN), 0.1% (wt/vol) LMNG and 0.1% (wt/vol) DDM, as these are most likely to maintain the MP in a biologically relevant conformation that is able to bind ligand. The amount of detergent to be used to solubilize the MP is dependent on the amount of cells used in the assay, but for highly expressed MPs, or when a high-specific activity radioligand is used, very few cells are required (e.g., 2 × 10 5 transiently transfected mammalian cells) and 0.1% (wt/vol) of the detergents above (final concentration) will lead to solubilization. If detergents of a high CMC are used (e.g., CHAPS), the detergent must be used at a concentration well above its CMC (e.g., 1% (wt/vol) CHAPS, which has a CMC of 0.6% (wt/vol)). Always include a negative control of detergent-solubilized cells that do not contain the protein of interest and, if possible, a negative control containing an unlabeled cold competitor at a 1,000-fold molar excess over the radiolabeled ligand.
(continued) (0.2-3 ml bed volume) that is processed rapidly using a centrifuge (such columns are commonly referred to as 'spin columns'). The MP-detergent-radioligand complex has a large molecular mass (typically ~130 kDa for a 35-kDa MP solubilized in DDM 59, 60 ) , so this appears in the flow-through, and the radioligand (typically <1.5 kDa) remains on the column. The choice of resin needs to be determined empirically (Box 3), and this choice is affected by the size and hydrophobicity of the radioligand. A problem that is often encountered when hydrophobic radioligands are used is that they partition into protein-free detergent micelles. This can give rise to very high backgrounds when the separation of MP-bound radioligands is performed using a spin assay that relies on size exclusion for separation of the free radioligand (Box 3). Protein-free micelles of DDM are typically 50-70 kDa in size, and thus they will appear in the flow-through of most spin columns, which typically use resins such as Sephadex G25 (size exclusion limit 25 kD) or Toyopearl HW40F. If the radioligand appears in the flow-through of the spin column, then a different radioligand (Fig. 4) or a different method for the determination of the amount of radioligand bound to the MP (Box 3), such as a scintillation proximity assay, should be used.
Once it has been determined that the radioligand remains in the resin of a spin column, the next step is to determine whether the radioligand bound to the detergent-solubilized receptor can
Box 3 | (Continued)
Object example: the serotonin transporter. For the serotonin transporter, three different inhibitors had been used previously in binding studies of the membrane-bound transporter: 125 I-RTI55, 3 H-imipramine and 3 H-paroxetine. These were all tested for the overexpressed transporter and could be used to give similar binding in membranes. However, when used on the serotonin transporter solubilized in DDM, the results appeared to be very different (Fig. 4) . 3 H-imipramine gave extremely high binding to the SERT-containing membranes in the presence of the competitive inhibitor cocaine. This commonly occurs when the ligand is very hydrophobic and interacts nonspecifically with the detergent micelle. 3 H-paroxetine binding was greatest in the sample containing SERT compared with the sample containing SERT and excess cocaine, but the ratio between them was 3:1, which is a poor assay and may lead to many false positives during the screening for thermostable mutants. By contrast, the ratio between the SERT and the SERT+cocaine values for 125 I-RTI55 was 100:1, which makes an ideal assay and was used to identify thermostable mutants 44 . Once the assay was developed in the Fisherbrand screening columns, it was further adapted to a 96-well plate format using Toyopearl HW40F medium (Steps 18-27) using a rationale similar to that described above. Commercial spin columns in a 96-well plate format are now available (Zeba 96-well spin desalting plates). We now use only the super-plus format. (a) Initial assay to define which radioligand could be used for the thermostability assay. Radioligands were added to cells at a concentration tenfold above their K D , in either the presence or absence of a cold competitor (1 mM cocaine) and incubated for 1 h; then SERT was solubilized in 1% (wt/vol) DDM at 4 °C. The lysate was passed through a spin column and the amount of radioligand in the flow-through (SERT-bound) was determined 45 . 125 I-RTI55 gave the best ratio between the bound radioligand measured in the presence or absence of cocaine. (b) Aliquots of cells were incubated with 125 I-RTI55 and then solubilized with different concentrations of DDM as indicated. After solubilization, the samples were heated for 30 min at different temperatures and then quenched on ice; then the amount of bound radioligand was determined 45 . The apparent T m for SERT varied with the amount of detergent: 1% (wt/vol) DDM, apparent T m 25 °C; 0.1% (wt/vol) DDM, apparent T m 28 °C; 0.01% (wt/vol) DDM, apparent T m 31 °C. Note that 0.01% (wt/vol) DDM probably failed to completely solubilize the membranes 42 , which perhaps caused the two-phase curve; these conditions would not be used for thermostabilizing a membrane protein. Error bars represent the s.e.m from an experiment performed in duplicate.
be detected using the spin assay. Typically for a first experiment in which nothing is known about the stability of the receptor, the radioligand is added to the mammalian cells expressing the receptor, it is allowed to bind and then detergent is added to a final concentration of 1% (wt/vol), which is a vast excess for solubilization but will ensure that all MPs are solubilized. We usually test four separate detergents first, namely digitonin, DDM, LMNG and DDM containing CHS (with a ratio of 1:30 (wt/wt) CHS: DDM). In our experience, these are among the mildest detergents for MPs, and they are therefore the most likely to maintain the receptor in a native conformation. Once binding has been detected, thermostability trials may be performed. Thermostability assays [12] [13] [14] entail heating the detergentsolubilized MP at a variety of different temperatures for a given time, and then determining how much functional MP remains, as determined by the radioligand-binding assay. Plotting a graph of the amount of functional detergent-solubilized receptor against the temperature at which the sample was heated should give rise to a sigmoidal curve, from which the apparent T m can be readily determined by nonlinear curve fitting (Fig. 4b) . The apparent T m is then defined as the temperature at which 50% of the functional MP remains after heating for a given length of time (30 min in our lab). These data can also be used to determine the absolute amount of functional MP expressed in the cells from the amount of radioligand bound to the unheated control. We have developed three different thermostability assays, which differ with respect to the order in which the radioligand and detergent are added in relation to the heating step (Fig. 3) . For the least stable MPs 44 , radioligand is added to cells, the receptor-radioligand complex is solubilized and the heating step is performed ('super-plus' format). In the 'plus' format, the receptor is solubilized and then the radioligand is added 40, 43 . In the 'minus' format, the MP is solubilized and heated in the absence of ligand, it is quenched on ice and then the radioligand is added [12] [13] [14] . The 'minus' format was the methodology initially used, but the 'plus' format has now superseded it, because adding the ligand before the heating step defines the conformation of the receptor to be stabilized. In reality, we now use only the 'super-plus' format because the targets that we are thermostabilizing are unstable in detergent solution in the absence of bound ligand 44 .
Thermostabilization of an MP
Once a robust thermostability assay has been developed and the apparent T m for the wild-type MP in a given detergent and buffer has been determined, the identification of thermostabilizing mutations can proceed. In the simplest methodology, Ala/Leu scanning mutagenesis is performed, in which each amino acid is changed to an alanine, unless it is already an alanine, in which case it is changed to a leucine [12] [13] [14] 40, 44 . All the mutants are verified by DNA sequencing, and then each mutant is expressed and its thermostability is determined. The simplest way to do this is to perform a two-point assay, in which the amount of MP remaining after heating at a temperature slightly above or at the apparent T m for 30 min is compared with that of an unheated control (Fig. 5) . For each batch of measurements, it is essential to include the wild-type MP as a control to allow normalization between different sets of measurements. Even after keeping the unheated detergent-solubilized MP on ice, particularly labile MPs can give variations in their binding between different experiments. Given this inherent instability of many MPs, depending on the day, we find that heating it at its apparent T m may result in anywhere between 40 and 60% of the receptor remaining functional. After the data for all 300 mutants have been obtained, the top 30-35 mutants are re-tested using a complete thermostability curve to determine their apparent T m . This is a more accurate assessment of the thermostability than the two-point assay. For GPCRs, we have found that between 5 and 9 % of the mutations are thermostabilizing, which allows the 16 most thermostable mutants to be used for the development of an optimally stable mutant.
The most rapid method for combining the mutations 40, 43 is to take the most stable mutant and then to add each of the other 15 mutations to it to make 15 double mutants (Fig. 6) . This method assumes additivity of the thermostable mutations, which occurs sufficiently often for this approach to work. The apparent T m of each of the 15 double mutants is determined from a thermostability curve. The most thermostable double mutant is then used as a basis for the construction of a triple mutant. When added together, some thermostable mutations do not result in a more thermostable double mutant, presumably because they are stabilizing slightly different conformations of the MP 43 . These nonadditive mutations are not used in the development of triple and quadruple mutants. How thermostable does an MP have to be? This is dictated according to why the thermostable MP is being produced in the first place, but the more thermostable the MP, the easier it will be to purify and crystallize it, or to use it in other assays such as surface plasmon resonance 61 . However, if time is of the essence, then it may not be necessary to produce MPs that are optimally stabilized. Judicious use of fusion proteins 62 , high-affinity ligands 10 , nanobodies 63 , truncations 60 and lipidic cubic phase crystallization strategies 64 may allow the crystallization of an MP that is only moderately stabilized. Unfortunately, there has not yet been a systematic benchmarking of the stability of all the GPCRs crystallized using a single assay system as has been performed for transporters 9 , which would have given some insight into the amount of stabilization required. Generally, we would advocate that purification and crystallization trials be performed in tandem with thermostabilization to facilitate the timely determination of the required structure.
Limitations of the thermostabilization protocol
For the thermostabilization procedure to work, it is essential that an assay be developed to detect MPs folded in a native conformation in detergent solution. This may be difficult if there are no high-affinity ligands or antibodies that bind only to the native conformation. Although the protocol below has been developed for the use of small radioligands, it is readily adaptable to the use of antibodies or other binding partners. In addition, the MP must be functionally expressed in sufficient quantities in mammalian cells to be detectable with the assay. With the exception of these caveats, the major limitations are the cost and time of the procedure, particularly for very large MPs containing >1,000 aa residues.
Comparisons with other methods
The first MP to be intentionally thermostabilized was diacylglycerol kinase (DGK) 65 . In this instance, mutants were screened for their ability to catalyze a reaction that was detected using a coupled enzyme assay with a colorimetric output. This is ideal for kinases, but it is not readily applicable to many receptors, transporters or ion channels. Parenthetically, the thermostable mutants of DGK never yielded crystals in vapor-diffusion crystallization trials that were sufficiently well ordered for structure determination. The structure of DGK was eventually determined using in meso crystallization methodology, in which crystals are grown in a monoolein cubic or sponge phase, with the most stable mutants yielding the best-diffracting crystals 66 .
An alternative strategy to thermostabilizing GPCRs was proposed by Plückthun and colleagues, based on the assumption that the more highly expressed an MP, the higher its thermostability would be. They reasoned that if this were true, then selecting for mutations that increased the expression of a GPCR would also lead to its themostablization. The NTSR1 expressed in E. coli, developed by Grisshammer and colleagues 67 , was mutated, its expression levels were determined by binding fluorescently labeled neurotensin and the cells with the highest expressing were isolated by flow cytometry 68 . Multiple rounds of mutagenesis and selection led to a highly expressed NTSR1 mutant, but the thermostability was only improved marginally by a factor of 3-4. This compares to the thermostabilization of the β 1 AR by over 1,000-fold 13 using the methodology of systematic mutagenesis and ligand binding assays described here. Improvements in the evolution methodology have now been made so that the selection is performed on detergent-solubilized receptors that are maintained within E. coli by an encapsulation process 69 . This allows the sorting by flow cytometry of detergent-stable receptors bound to fluorescent ligand, and multiple rounds of evolution yield highly stable receptors that can be crystallized. Interestingly, the structure of NTSR1 thermostabilized by multiple rounds of evolution in E. coli appears to be conformationally thermostabilized in an agonist-bound inactive state 27 , whereas NTSR1 thermostabilized by Grisshammer and colleagues is in an active-intermediate conformation 26 . The advantage of the evolution methodology in E. coli is that it is cheap to develop a thermostable receptor, although it does require a good flow cytometry facility. The disadvantage is that the target MP must be able to be expressed in either E. coli or yeast, and although some MPs can be expressed in these microorganisms many require the optimal folding environment of a mammalian cell to attain a native structure 47 . In addition, high-affinity fluorescent ligands are required for this process.
Applications of thermostabilized MPs
The properties of thermostabilized GPCRs make them ideal for structural analyses by X-ray crystallography, NMR or electron cryo-microscopy (cryo-EM), other biophysical analyses and drug discovery. Thermostabilized receptors are all far more stable in The most thermostable single mutation (mutant A, green diamond) was combined with each of the next 15 most stabilizing mutations (B-P) and their stabilities were determined (blue diamonds). The most stable double mutant (mutant AB, dark blue diamond) was then combined with additive mutations that also improved the thermostability of mutant A (the predicted T m was similar to the experimental T m ), to produce triple mutants (red diamond), the most stable of which was mutant ABF. In the paper describing this work 40 , mutant A is GL0, mutant AB is GL10 and mutant ABF is GL23. short-chain detergents than the wild-type receptors (Fig. 7) , which allowed the structure determination of β 1 AR in octylthioglucoside 20 and of A 2A R in nonylglucoside 23 . In addition, because the receptors are so stable, they can also be crystallized in the presence of ligands with low affinity in the 1-to 10-µM range 16, 25 . The detergent stability of the thermostabilized receptors also makes them ideal for NMR studies on the dynamics of MPs in solution and potentially structure determination. For example, ultrastable β 1 AR 41 yields well-resolved NMR spectra that have been used to study the global conformation changes of the receptor upon agonist binding 70 . Applications in the structure determination of thermostabilized MPs by cryo-EM have not yet been explored, but it is anticipated that the flexibility of many MPs may limit the resolution of particularly dynamic regions, which could be resolved after thermostabilization. For example, the recent structures of both P-type and V-type ATP synthases 71,72 determined by single-particle cryo-EM found that the a-subunit was highly flexible, resulting in this region being the most poorly resolved part of the structure. The thermostabilized receptors have also proven to be ideal for studies using surface plasmon resonance 61 , in which the binding and dissociation of small ligands can be assessed and is an essential component of the structure-based drug design, as applied to GPCRs 73, 74 . Finally, the thermostable receptors have been used for screening compound libraries by NMR, which identified novel chemotypes that bind to β 1 AR differently from other ligands, as observed in the crystal structures 17 . A receptor thermostabilized in the antagonist-bound state still binds antagonists with similar affinity to that of the wild-type receptor and the rank order of potency is maintained, but the binding of agonists is often two to three orders of magnitude weaker 12, 13, 30, 75 . The converse is true for receptors stabilized in the agonist-bound state 40 . However, these effects on receptor pharmacology are due to the biased conformation of the receptors with the ligand-binding pockets being unperturbed 11 . Similarly, thermostabilized SERT is locked in a single conformation and is incapable of transporting substrate, but it still binds inhibitors with high affinity 44 . Complete medium To 500 ml of DMEM, add 50 ml of certified FBS and 0.5 ml of blasticidin stock solution in a biosafety cabinet. Store the medium at 4 °C for up to a month. Selection medium To 500 ml of DMEM, add 50 ml of certified FBS, 1 ml of Zeocin (200 µg/ml final concentration) and 0.5 ml of blasticidin stock solution in a biosafety cabinet. Store the medium at 4 °C for up to a month. ! cautIon Both Zeocin and blasticidin are toxic. Wear a lab coat, gloves and eye protection. Induction medium To 1 ml of selection medium, add 1 µl of tetracycline stock solution to obtain a 1 µg/ml final concentration.  crItIcal Freshly prepare the medium for each use, and do not store it. Glucose solution (20% (wt/vol)) Dissolve 20 g of glucose in 100 ml of autoclaved water. Filter-sterilize the solution with a 0.22-µm filter.
Store the solution at 20 °C for up to 6 months. LB medium Add 10 g of tryptone, 5 g of yeast extract and 10 g of NaCl to 800 ml of dH 2 O, and stir until it is dissolved. Add water in a measuring cylinder to make the final volume up to 1 liter. Autoclave the medium for 20 min at 121 °C, and store it at 4 °C for up to 6 months. PCR reaction mix Add 2.45 ml of PCR-grade water, 500 µl of 10× KOD buffer, 500 µl of 0.2 mM dNTPs, 300 µl of 1.5 mM MgSO 4 and 450 µl of 9% (vol/vol) DMSO. Mix it well, and then add 100 µl of KOD enzyme (2.5 units per µl). Mix the contents well and use it immediately. 4.3 ml is required per 96-well plate. PEI stock (1 mg/ml) Dissolve 50 mg of PEI in 50 ml of PBS. Filter-sterilize the solution inside a biological safety cabinet with a 50-ml Steriflip-GP. Store the solution in 1-ml aliquots in autoclaved tubes at −20 °C for up to 1 year. ! cautIon PEI is a serious skin and eye irritant, so wear appropriate protective equipment. SOC medium Add 20 mM glucose 20% (wt/vol) to SOB medium. Filter-sterilize the medium using a 0.22-µm filter, and store it at 20 °C for up to 6 months. Cell buffer Mix 20 mM Tris, pH 7.4, and 150 mM NaCl. Add complete EDTA-free protease inhibitors according to the manufacturer's instructions immediately before use. Freshly prepare the buffer. Detergent stock solutions Dissolve 10 g of DDM, LMNG or GDN in water, and make up to a final volume of 100 ml. Store it for up to 1 year at −20 °C in aliquots to avoid repeated freeze-thaw cycles. ! cautIon The powder is a respiratory sensitizer, so handle it in a fume hood. Digitonin solution Add 5 g of digitonin to 90 ml of water, boil the mixture for 2 min, cool it on ice, make it up to a final volume of 100 ml and filter it through a 0.22-µm syringe filter. Store the solution for up to 1 year at −20 °C in small aliquots to avoid repeated freeze-thaw cycles. ! cautIon The powder is a respiratory sensitizer, so handle it in a fume hood.
• • • • proceDure ala/leu scanning mutagenesis • tIMInG 1 week  crItIcal The protocol given below is for mutating the rat SERT, which is fused at its C terminus to mCherry, in pcDNA4/TO (Invitrogen) with a total insert size of 2.5 kb (ref. 44 ). The plasmid plus insert is 8 kb in size, it is of low copy number and it contains an ampicillin resistance gene. Appropriate adjustments will be required in the protocol for the use of plasmids of different sizes, different copy number and different antibiotic resistance. Kits for the PCR reaction can be purchased, but it is cheaper to use individual components that are bought separately. However, if the user is not already familiar with PCR mutagenesis, it is worth constructing a small subset of mutants using the protocol below to become familiar with the process on a small scale. Mistakes in 96-well plate protocols are costly in both time and money. The timing given is for a small number of mutants. For timing for a complete Ala/Leu scan, see the TIMING section below. 1| Design the mutagenic primers to change each desired amino acid residue to, for example, alanine. If a residue is already an alanine, then change it to a bulkier amino acid, such as leucine. Forward and reverse primers are designed using an in-house proprietary program (OptimusPrimer 2.0) based on Zheng et al. 76 , but similar tools are available on the Internet (e.g., primerX (http://www.bioinformatics.org/primerx/) or the QuikChange protocol from Agilent (http://www. agilent.com/genomics/qcpd)). Primers (desalted, but not purified) should be ordered in 96-well plates as 100 µM solutions, with the forward and reverse primers in separate plates and primer pairs in identical well positions to facilitate setting up the mutagenic reactions.
2|
Combine complementary forward and reverse primers in the same well of a new 96-well plate, and dilute in water to obtain a final concentration of each primer of 10 µM.
3|
Using a multichannel pipette, add 43 µl of PCR mix, 5 µl of the oligonucleotide primer mix from Step 2 (forward primer and reverse primer, 1:1 (vol:vol)) and 2 µl (20 ng) of template plasmid to a new 96-well plate.
4|
Place the mixture in a 96-well PCR block and run the following cycle: 
7|
After transformation, transfer the mix to 1 ml of prewarmed SOC medium (37 °C) in a 96-well block, and allow it to grow, shaking at 37 °C for 1 h.
8|
Centrifuge the cells at 2250g for 10 min at 4 °C in the 96-well block, remove ~900 µl of the media supernatant, resuspend the cells by gently pipetting up and down with a multichannel pipette and then plate out the cells on a 2xTY agar 90-mm plate containing 100 µg/ml of ampicillin.
9|
On the following day, pick two colonies from each plate and place them into 7 ml of LB medium containing 100 µg/ml of ampicillin in a 10-ml 24-well deep-well plate. Grow the culture overnight at 37 °C with shaking. ? trouBlesHootInG 10| Prepare miniprep DNA using a commercial kit (e.g., QIAGEN Miniprep Kit) and following the manufacturer's protocol.  pause poInt The samples can be stored at −20 °C for several days.
11| Sequence the whole region of the mutated cDNA to ensure that only the single desired mutation is present. We find that the sequencing is necessary because of a reasonably high frequency of additional mutations in the primer site, particularly in regions with a high GC content.
transient transfection of mutants into mammalian cells • tIMInG 4 d
 crItIcal Prior optimization of this step is essential for each target (Box 2), which may mean varying parameters in the protocol below. The protocol given below is for expressing the rat SERT under the control of a tetracycline-inducible CMV promoter in plasmid pcDNA4/TO. This system has proven to be the most useful for expressing a wide variety of mammalian MPs in mammalian cells in a fully functional form 46 . Parameters that need to be optimized include transfection reagent (PEI, GeneJuice or Lipofectamine), the amount of plasmid per transfection (0.1-3 µg), time before harvesting (12-48 h ) and the amount of tetracycline needed to induce expression (0.1-3 µg/ml). The timing given is for a small number of mutants. For timing for a complete Ala/Leu scan, see the TIMING section below. 12| Prepare a plasmid maxi-prep for each plasmid to be transfected using a commercial kit-e.g., QIAGEN-using the manufacturer's protocol. 15| Add tetracycline to obtain a final concentration of 1 µg per ml (1 µl of a 1 mg/ml tetracycline stock). Incubate the cells for 24 h at 37 °C.
16|
Image the cells using a fluorescence microscope to determine whether the transfection has worked (positive control) and whether the mutants show defects in expression or cell trafficking. Trafficking defects could be a sign that the mutant is misfolded and inactive (Box 2). ? trouBlesHootInG
17|
Harvest the cells by using a cell scraper, pipette them into a 15-ml centrifuge tube, pellet the cells (500g, 5 min, 4 °C) and resuspend them in PBS (4 °C) containing complete protease inhibitors to obtain a final concentration of 10 6 cells per ml.
If the specific activity of the radioligand is low, it may be necessary to store the cells at a higher concentration-e.g., 10 7 cells per ml-to ensure that sufficient cells are used in assays.  pause poInt The samples can be stored at −20 °C for several days or at −80 °C for several months after snap-freezing in liquid nitrogen. Store the cells in small aliquots to limit the number of freeze-thaw cycles to ~3.
two-point thermostability assay of detergent-solubilized mutants • tIMInG 1 d  crItIcal The protocol below is for 125 I-RTI55-bound SERT solubilized in 0.1% (wt/vol) DDM and is performed in a 96-well plate (super-plus protocol) 44 . This step will require extensive optimization to be performed on other MPs, with the parameters to be varied being the number of cells per assay point, the concentration of the radioligand, the buffer composition, the concentration of detergent, the type of detergent and the type of resin used (Box 3). The timing given is for a small number of mutants. For the timing of a complete Ala/Leu scan, see the TIMING section below. 18| Add 125 I-RTI55 (1 nM final concentration-i.e., 10× K D ) to 10 5 cells in PBS containing protease inhibitors in a final volume of 50 µl, with one mutant per well of a 96-well plate. Ensure that two wells include positive controls (wild-type SERT), which should be included in each 96-well plate in positions A1 and H11. In addition, ensure that two wells include negative controls (untransfected HEK293 cells), which should be included in each 96-well plate in positions A2 and H12. Prepare duplicate plates: one will be incubated at the apparent T m and the other will represent an unheated control plate. Incubate the cells for 1 h on ice.  crItIcal step Cells must be resuspended homogeneously; otherwise, clumps of cells can cause irreproducible assays. Passage of the cells through a 26-gauge syringe containing two 90° bends helps to break up clumps or, alternatively, the cells can be sonicated with a narrow-tipped sonicator probe for 2 s.
19| Add 5 µl of 1% (wt/vol) DDM to each well using a multichannel pipette. Incubate the cells on ice for 1 h.  crItIcal step The final concentration of detergent needs to be optimized, and it may vary between 0.1 and 1% (wt/vol) DDM, or another detergent may be required (Box 3).
20|
Incubate the 96-well plates for 30 min in a PCR block at 32 °C. Plates for unheated controls are left on ice. After exactly 30 min, place the tubes in a metal block precooled to ice temperature. A metal block is not essential, but it maximizes the rate of cooling.  crItIcal step For reproducibility between assays, the duration of the heating step must be exactly 30 min. If you are handling multiple plates, ensure that plate 1 is put at 32 °C at t = 0, and then subsequent plates at 15-s intervals; plates are then removed in exactly the same order, with 15-sec intervals between the plates. Steps 18-20 must be performed without any waiting between the steps. All pipetting must be performed accurately to ensure that equal volumes of solubilized SERT are analyzed.
21|
During the above incubation times, prepare a 96-well spin plate by adding 300 µl of Toyopearl HW-40F size-exclusion chromatography (SEC) medium to each well (Box 3).
22|
After the heating step is completed (Step 20) , centrifuge the spin plates containing the SEC medium at 70g for 1 min at 4 °C with a 96-well plate underneath to collect the flow-through (discard). Replace the spin plate over a new 96-well plate. The SEC medium should appear dry (opaque white).  crItIcal step A swing-out rotor must be used, and the timing and speed must be consistent for all assays.
23|
Immediately load 50 µl of solubilized SERT from Step 20 using a multichannel pipette. As soon as both plates are fully loaded, centrifuge them at 70g for 1 min at 4 °C.  crItIcal step A swing-out rotor must be used, and the timing and speed must be consistent for all assays.
24|
Immediately add 20 µl of solubilization buffer to each well using a multichannel pipette. As soon as both plates are fully loaded, centrifuge them at 765g for 5 min at 4 °C.  crItIcal step A swing-out rotor must be used, and the timing and speed must be consistent for all assays.
25|
Carefully remove the spin plate containing the SEC medium and the 'free' 125 I-RTI55, and discard it (per applicable guidelines and regulations for radioactive waste).
26|
Transfer the flow-through containing the 125 I-RTI55-bound SERT to a 5-ml scintillation vial and add 4 ml of UltimaGold scintillant; count for 1 min in a scintillation counter.
27| Analyze the data (Box 4).
? trouBlesHootInG Determination of the apparent T m of the most thermostable mutants • tIMInG 1 d  crItIcal All the mutants that appear to be substantially more thermostable than the wild-type SERT should be reanalyzed to determine their stability with respect to one another by determining their apparent T m values. This is more accurate than the two-point thermostability assay in Steps 18-27. The timing given is for a small number of mutants. For the timing of a complete Ala/Leu scan, see the TIMING section below. 28| Select mutants that are substantially more stable than the wild type according to the data from Step 27. Add 125 I-RTI55 (1 nM final concentration-i.e., 10× K D ) to 10 6 cells in PBS containing protease inhibitors in a final volume of 500 µl, with each mutant in a 1.5-ml microcentrifuge tube. Ensure that a similar tube containing the wild-type SERT is prepared for each batch of mutants tested. Incubate the mixture for 1 h on ice.
29| Add 5 µl of 10% (wt/vol) DDM to each tube and mix by gently pipetting up and down (see Box 3 in regard to the amount of detergent used). Incubate the mixture on ice for 1 h.
30| Divide the samples into six different precooled PCR strips (12 tubes per strip), with each strip containing one 60-µl tube each of 11 detergent-solubilized mutants and one tube containing wild-type SERT. The tubes must be precooled to 0-6 °C, and this is best performed in a cold room with the pipette tips also precooled.
31|
Incubate five PCR strips at an appropriate temperature for 30 min in a PCR block-e.g., 30 °C (apparent T m ), 20, 40, 50 and 70 °C. After exactly 30 min, place the tubes in a CoolRack precooled to ice temperature.
32|
Perform the assay again, as described in Steps 21-27.
33|
Analyze the data and determine the apparent T m of each mutant by fitting the data to a variable-slope Boltzmann distribution using, for example, the program GraphPad Prism. This will also give an estimate of the error of the curve fitting, and the whole experiment should be repeated for accuracy. ? trouBlesHootInG 34| (Optional) The thermostable mutants may be improved upon by trying other amino acid residues at the same position as the thermostabilizing alanine residue (Fig 5) . For example, the mutation I129A thermostabilized β 1 AR, but I129V was better; conversely, I55A thermostabilized β 1 AR, but I55G was strongly destabilizing 13 NA, not applicable. Consideration of the data suggests that mutations S and T are probably thermostabilizing but that mutations V and Z are probably false positives due to the spuriously low d.p.m. 1 for mutant V and the near-background binding observed for mutant Z. Mutation U could be thermostabilizing, but it needs a more detailed analysis. Mutant W has similar properties to those of the wild-type protein, whereas mutant X has been destabilized by the mutation. Mutant Y does not show substantial binding at 4 °C, which suggests that folding was impaired, the protein may be extremely unstable or the mutation is in the binding site and either prevents ligand binding or markedly alters the apparent K D for the ligand. Mutants X and Y are interesting in their own right; similar results from the thermostabilization of β 1 AR identified amino acid residues involved in binding the highly conserved intramembrane Na + ion and associated water molecules 18 .
Two courses of action present themselves from these data. First, mutant V should be retested on a two-point thermostability assay, whereas mutants S, T and U should be tested on a full seven-point thermostability assay to determine an apparent T m (Steps 28-33). Second, if mutant S is indeed thermostabilizing, it may be worth investigating other mutations at this site to improve expression levels. There is no substantial correlation between stability and expression levels 11 , which implies that if one mutation is thermostabiling, but markedly decreases expression levels, substitution with another amino acid residue may maintain the thermostabilizing effect and restore expression levels. This was observed for the thermostabilizing H103A mutation in NTSR1 that reduced expression levels five-fold, whereas the substitution H103S restored expression levels and maintained the increase in thermostability 14 . thermostable, use each as a starting point for making the double mutants. Take each of the next 15 thermostable mutations (i.e., mutations B-P) and use the mutagenic primers (Step 1) to construct all the possible double mutants with mutant A. Make sure that the primers do not overlap with mutation A, and if they do, construct new primers as appropriate. Perform mutagenesis (Steps 1-11 
36|
Carefully analyze the apparent T m values of each of the double mutants from Step 35, and identify those double mutants for which the mutation is additive or nearly additive. In this example, the best double mutant was AB and the additive mutants were C, E, F, G, J, L, N and P (Fig. 6) . ? trouBlesHootInG 37| Repeat Steps 35 and 36 to make triple mutants, but use mutant AB as the starting point and only the additive mutants C, E, F, G, J, L, N and P in the mutagenic process. 
38|

antIcIpateD results
The thermostability assay (Fig. 4) provides a good indication of how stable an MP is and how much more thermostabilization is required to improve the likelihood of obtaining crystals. For example, if the thermostability can be measured only in digitonin with a high-affinity ligand bound, this suggests that the MP is unstable and will need considerable thermostabilization before the structure can be determined. If the thermostability in 1% (wt/vol) DDM in the absence of any ligand is >40 °C, then there is a reasonable probability of obtaining crystals, provided that high-affinity ligands are available. Creating the Ala/Leu scan mutants throughout the receptor is standard molecular biology and is merely tedious with a guaranteed outcome. Normally, we find that the first ~70% of the mutants can be obtained from the conditions given in the protocol. The majority of the remaining mutants can be obtained by altering the conditions of the primer annealing. The remaining handful of mutants can be more challenging and may require new primers to be designed, although it is now quicker just to get these mutant cDNAs synthesized in their entirety. Screening the mutants using the two-point thermostability assay usually produces plenty of potential thermostabilizing mutations [12] [13] [14] 30, 40, 41, 43 . These need to be rescreened using the seven-point thermostability assay to remove any false positives and to accurately determine an apparent T m . From this step we find that ~5-9% of the mutants are more stable than the native receptor, although the figure was much lower during the thermostabilization of SERT (2%; ref. 44) . Combining the mutations pairwise with the most thermostable mutation rapidly identifies those mutations that are additive and that, upon further combination, will produce a thermostable MP 40, 43 . We normally stop recombining mutations when there is no further measurable difference in apparent T m . How stable does a MP have to be to get crystals? The original benchmark that we used was rhodopsin, which is still the only native GPCR to have its structure determined 77 and has an apparent T m of ~55 °C (30 min heating in DDM) 78 . Note that this value cannot be compared with thermostability assays determined by other techniques, e.g., the CPM assay 79 , and can be compared directly only with assays for which the heating step is 30 min, i.e., data from the Pluckthun laboratory, where samples are heated for 20 min, yield higher apparent T m values 80, 81 than if the heating step were for 30 min. It is important to remember that rhodopsin contains a covalently bound ligand, so the thermostability is equivalent to that of a GPCR assayed in the super-plus format. The benchmark of rhodopsin stability is probably reasonable if crystallization is to be attempted in detergent solution by vapor diffusion. However, GPCRs with lower apparent T m values could possibly be crystallized using the lipidic cubic phase technology as T4L or BRIL fusion proteins, because stabilizing agents such as lipids, CHS or cholesterol can be added at high concentrations without inhibiting crystal formation, as has been observed in detergent-based vapor diffusion crystallization trials. autHor conrtIButIons All authors contributed to the development of techniques described in this paper. C.G.T. wrote the manuscript and coordinated contributions from all the other authors.
coMpetInG FInancIal Interests The authors declare competing financial interests: details are available in the online version of the paper.
